Craig Eagle, MD, FRACP, FRCPA from Guardant Health. In this video, he explains that the Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer.
The TRIUMPH study looked at the efficacy of pertuzumab with trastuzumab in patients with mCRC who had HER2 amplification as established by circulating tumor DNA (ctDNA) analysis or tissue genotyping. EGFR-targeting monoclonal antibodies had previously been used to treat all of the patients. Additional exploratory studies were conducted to explore if ctDNA genotyping might be used to predict treatment success, follow response, and uncover resistance mechanisms.
While the efficacy of HER2-directed therapy was similar in patients with HER2 amplification detected in tissue or ctDNA, the ctDNA analysis had the added benefit of identifying additional alterations that predicted which patients would benefit from HER2-directed therapy, according to the study, which builds on the results of the SCRUM-Japan GOZILA study from last year. Furthermore, ctDNA decreases after treatment commencement were linked to radiographic improvement, and ctDNA genotyping revealed resistance-related mutations after illness onset.
The Guardant360 liquid biopsy test is part of the market-leading Guardant360 portfolio, which offers oncologists end-to-end testing options that include everything from therapy selection to treatment response monitoring. The portfolio includes the Guardant360® CDx test, the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid tumor malignancies, and Guardant360 TissueNextTM, a novel comprehensive genomic profiling option for oncologists. Guardant360 ResponseTM, the first blood-only liquid biopsy, allows oncologists to see molecular reactivity, or changes in ctDNA levels, from a single blood sample, giving them an early indicator of whether a patient is responding to therapy. Oncologists can use this tool to help patients with late-stage or metastatic cancer decide whether to continue, stop, or explore alternative treatment options.
The Guardant360 blood test has been widely recognized for blood-based comprehensive genomic profiling, with over 250 peer-reviewed publications and over 60 clinical outcomes studies (CGP). More than 9,000 oncologists have put their faith in it, with over 150,000 tests completed so far.